In a study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, the small-molecule KRAS G12C inhibitor sotorasib combined with the ...

Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an ...

KRAS mutations are present in up to 45% of colorectal cancer cases, but fewer than 10% involve the KRAS G12C mutation. Sotorasib targets the KRAS G12C protein specifically and is the first KRAS G12C ...

The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC) has come more than two months ahead of ...

Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...

Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the disease. The drug was the first targeted at the ...

Nevertheless, efforts to advance KRAS as a therapeutic target began to bear fruit in the last decade, and two selective inhibitors of the KRAS-G12C oncoprotein, sotorasib and adagrasib ...

Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs. Bimetallic metal-organic framework as an ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

Of these, fewer than 10% involve the KRAS G12C mutation. Sotorasib targets the KRAS G12C protein specifically and is the first KRAS G12C inhibitor to be FDA-approved for clinical use. It works by ...